LIVER FUNCTIONS PROFILE OF TUBERCULOSIS PATIENTS IN INDONESIA DURING ANTITUBERCULOSIS TREATMENT
DOI:
https://doi.org/10.22159/ijap.2024.v16s1.22Keywords:
Liver Functions, Tuberculosis, IndonesiaAbstract
Objective: The objective of this study is to define the profile of liver function of tuberculosis patients during the treatment.
Methods: We conducted the longitudinal study with adult tuberculosis patients treated with the first line of antituberculosis as the inclusion criteria. The pregnant and patients with comorbidities which related to liver function were excluded. We measured the total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) over the 2nd, 4th, and 6th mo of the treatment.
Results: We recruited 202 patients, with 58.91% male patients, and the mean age was 39.91 (SD: 17.18) years old. As 9% of tuberculosis patients experienced increased levels of bilirubin, AST, and ALT, and 50% among them experienced increased levels of bilirubin, AST, and ALT starting from 2nd mo of the treatment. The total bilirubin level in the 2nd,4th, and 6th mo were 0.57, 0.59 and 0.67 mg/dl, respectively. The AST levels were 27, 22, and 26 U/l in 2nd,4th and 6th mo, respectively, and the ALT levels were 21,19 and 25 U/l in 2nd,4th and 6th mo, respectively. At the end of the treatment, around 4.5% tuberculosis patients experienced high levels of bilirubin, AST and ALT.
Conclusion: The monitoring treatment for tuberculosis patients should be conducted until the end of the treatment because the level of bilirubin, AST, and ALT increased after 6th mo of treatment.
Downloads
References
WHO. Global tuberculosis report; 2022. Available from: https://www.who.int/publications/digital/global-tuberculosis-report-2021.
Tesfahuneygn G, Medhin G, Legesse M. Adherence to anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC Res Notes. 2015 Sep;8:503. doi: 10.1186/s13104-015-1452-x, PMID 26420164.
Prasanna T, Jeyashree K, Chinnakali P, Bahurupi Y, Vasudevan K, Das M. Catastrophic costs of tuberculosis care: a mixed methods study from puducherry, India. Glob Health Action. 2018;11(1):1477493. doi: 10.1080/16549716.2018.1477493, PMID 29902134.
Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in thai patients. Int J Tuberc Lung Dis. 2016 Oct;20(10):1364-9. doi: 10.5588/ijtld.15.0310, PMID 27725049.
Abbara A, Chitty S, Roe JK, Ghani R, Collin SM, Ritchie A. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017 Mar;17(1):231. doi: 10.1186/s12879-017-2330-z, PMID 28340562.
Patterson B, Abbara A, Collin S, Henderson M, Shehata M, Gorgui Naguib H. Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests. J Infect. 2021 Feb;82(2):240-4. doi: 10.1016/j.jinf.2020.09.038, PMID 33271167.
Latief M, Dar WR, Sofi N, Dar IA, Kasana B, Hussain M. Novel risk factors and early detection of anti-tubercular treatment induced liver injury-looking beyond American Thoracic Society Guidelines. Indian J Tuberc. 2017 Jan;64(1):26-32. doi: 10.1016/j.ijtb.2016.11.002, PMID 28166913.
Raj Mani SS, Iyyadurai R, Mishra AK, Manjunath K, Prasad J, Lakshmanan J. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system. Int J Mycobacteriol. 2021;10(2):116-21. doi: 10.4103/ijmy.ijmy_15_21, PMID 34558461.
Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study. Med Sci Monit. 2020 Mar;26:e920350. doi: 10.12659/MSM.920350, PMID 32145061.
Chang TE, Huang YS, Su WJ, Perng CL, Huang YH, Hou MC. The role of regular liver function monitoring in antituberculosis drug-induced liver injury. J Chin Med Assoc. 2019 Jul;82(7):535-40. doi: 10.1097/JCMA.0000000000000119, PMID 31274784.
Subbalaxmi MVS, Soanker R, Lakshmi AV. Evaluation of risk factors for development of anti-tubercular therapy-induced hepatotoxicity: a prospective study. Curr Drug Saf. 2020;15(3):198-204. doi: 10.2174/1574886315666200626164554, PMID 32589563.
Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int. 2019 Jan;39(1):31-41. doi: 10.1111/liv.13931, PMID 30003672.
Bjornsson HK, Bjornsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022 Mar;97:26-31. doi: 10.1016/j.ejim.2021.10.035, PMID 34772600.
Perwitasari DA. Genotype polymorphisms of Nat2 and Cyp2e1 genes associated with drug-induced liver injury (Dili) in Indonesian tuberculosis patients. Indonesian J Pharm. 2016;27(1):22-7. doi: 10.14499/indonesianjpharm27iss1pp22. Available from: http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/825.
Perwitasari DA, Irham LM, Darmawan E, Mulyani UA, Atthobari J. CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients. Indian J Tuberc. 2016 Jul;63(3):139-43. doi: 10.1016/j.ijtb.2016.08.001, PMID 27865233.
Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016 Jun;61(6):533-7. doi: 10.1038/jhg.2016.10, PMID 26911349.
Hou W, Nsengimana B, Yan C, Nashan B, Han S. Involvement of endoplasmic reticulum stress in rifampicin-induced liver injury. Front Pharmacol. 2022;13:1022809. doi: 10.3389/fphar.2022.1022809, PMID 36339603.
Bjornsson ES. Clinical management of patients with drug-induced liver injury (DILI). United European Gastroenterol J. 2021 Sep;9(7):781-6. doi: 10.1002/ueg2.12113, PMID 35084797.
Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M. A randomized controlled trial of intravenous n-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin Infect Dis. 2021;73(9):e3377-83. doi: 10.1093/cid/ciaa1255, PMID 32845997.
Wu S, Xia Y, Lv X, Tang S, Yang Z, Zhang Y. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients. J Gastroenterol Hepatol. 2015 Mar;30(3):540-5. doi: 10.1111/jgh.12717, PMID 25160904.
Published
How to Cite
Issue
Section
Copyright (c) 2024 PERWITASARI DA, SETIAWAN D., SAFARIA T., DANIA H., FARIDAH IN, IRHAM LM
This work is licensed under a Creative Commons Attribution 4.0 International License.
